The effect of prophylactic chemotherapy on treatment outcome of postmolar gestational trophoblastic neoplasia

被引：0
作者：
Yuanyuan Liu
Yaqiong Ye
Xiaodong Cheng
Weiguo Lu
Xing Xie
Xinyu Wang
Xiao Li
机构：
[1] Zhejiang University School of Medicine,Department of Gynecologic Oncology, Women’s Hospital
[2] Zhejiang University School of Medicine,Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women’s Hospital
[3] Cancer Research Institute of Zhejiang University,undefined
[4] Ninghai Second People’s Hospital,undefined
[5] Center for Uterine Cancer Diagnosis and Therapy Research of Zhejiang Province,undefined
来源：
BMC Women's Health | / 23卷
关键词：
Hydatidiform mole; Prophylactic chemotherapy; Gestational trophoblastic neoplasia; Chemotherapy resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 146 条
[1]  
Ngan HYS(2021)Diagnosis and management of gestational trophoblastic disease: 2021 update Int J Gynaecol Obstet 155 86-93
[2]  
Seckl MJ(1996)Chorionic tumors N Engl J Med 335 1740-1748
[3]  
Berkowitz RS(2012)Trophoblastic disease Int J Gynaecol Obstet 119 130-136
[4]  
Xiang Y(1990)Persistent gestational trophoblastic tumor after partial hydatidiform mole Gynecol Oncol 36 358-362
[5]  
Golfier F(2006)Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy J Reprod Med 51 902-906
[6]  
Sekharan PK(2006)Persistent gestational trophoblastic neoplasia after partial hydatidiform mole: incidence and outcome J Reprod Med 51 764-766
[7]  
Berkowitz RS(2019)Gestational trophoblastic neoplasia, version 2.2019, NCCN Clinical Practice Guidelines in Oncology J Natl Comper Canc Netw 17 1374-1391
[8]  
Goldstein DP(1981)Management of molar pregnancy J Reprod Med 26 208-212
[9]  
Ngan HY(2001)Prophylactic actinomycin D for high-risk complete hydatidiform mole J Reprod Med 46 110-116
[10]  
Kohorn EI(2009)Gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective, secure and low-cost approach without adverse effects on compliance to general follow-up or subsequent treatment Gynecol Oncol 114 299-305
12345678910